Document Detail


Identifying treatments that halt progression of pulmonary disease in cystic fibrosis.
MedLine Citation:
PMID:  9029632     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rapid progress in cystic fibrosis research affords the possibility of halting the progress of the lung disease. We used data from 215 patients who had sputum cultures negative for Burkholderia cepacia, at least one outpatient pulmonary function test during 1990, and at least one test a year later to estimate the number of subjects and study duration required to demonstrate that a hypothetical treatment reduces the rate of decline of forced expiratory volume in 1 s (FEV1) to zero. Mean rate of decline of FEV1 (percent predicted) was about 2% predicted per year. Variability decreases with increasing time of observation. For a 1-y study, with alpha = 0.05 and beta = 0.20, over 550 patients must complete the study in each group to show that a treatment halts pulmonary decline. For a 2-y study, 86 subjects in each group are required, and for 4 y, 65. Increasing the number of data points used to determine the rate of decline of FEV1 had only small effect on sample size. Use of pulmonary function data collected at regular intervals for research purposes did not alter these conclusions. Higher initial FEV1 was associated with a greater rate of decline, and among patients with initial FEV1 > 60% predicted, younger subjects had a faster decline than did older subjects. Thus, fewer subjects will be required to detect a complete halt in progression of lung disease if the patients are young and have mild pulmonary disease.
Authors:
P B Davis; P J Byard; M W Konstan
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Pediatric research     Volume:  41     ISSN:  0031-3998     ISO Abbreviation:  Pediatr. Res.     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-05-08     Completed Date:  1997-05-08     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0100714     Medline TA:  Pediatr Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  161-5     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Childrens Hospital, Cleveland, Ohio 44106, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Child
Child, Preschool
Cystic Fibrosis / drug therapy*,  pathology
Disease Progression
Humans
Ibuprofen / therapeutic use*
Linear Models
Lung / pathology*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
P30 DK27651/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
15687-27-1/Ibuprofen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mycotoxin fumonisin B1 stimulates nitric oxide production in a murine macrophage cell line.
Next Document:  Actin depolymerization is developmentally regulated in rat type II cells exposed to terbutaline.